Meeting
2022 ASCO Annual Meeting
Phase I trial of an alpha-lactalbumin vaccine in patients with moderate- to high-risk operable triple-negative breast cancer (TNBC).
Authors
George Thomas Budd
Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH
George Thomas Budd , Justin M. Johnson , Emily Esakov Rhoades , Halle C. F. Moore , Megan Lynn Kruse , Erin Elizabeth Roesch , Jame Abraham , Brenna Elliott , Donna Lach , Vincent K. Tuohy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT04674306
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS1125)
DOI
10.1200/JCO.2022.40.16_suppl.TPS1125
Abstract #
TPS1125
Poster Bd #
493a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 dose-escalation, dose-expansion trial of intratumoral HER2- and HER3-primed dendritic cells injections for the treatment of early-stage TNBC and HR low positive breast cancer: DecipHER trial.
First Author: Ricardo L Costa
Poster
2014 Breast Cancer Symposium
A phase 1 study of dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple-negative breast cancer.
First Author: Zahi Mitri
Poster
2013 ASCO Annual Meeting
A phase I study of neoadjuvant chemotherapy (NCT) with the gamma secretase (GS) inhibitor RO4929097 in combination with paclitaxel (P) and carboplatin (C) in women with triple-negative breast cancer (TNBC).
First Author: Ewa Mrozek
Poster
2013 ASCO Annual Meeting
Novel toxicity endpoint for dose-finding designs evaluating molecularly targeted agents (MTA).
First Author: Monia Ezzalfani